Medical cost, incidence rate, and treatment status of gastroesophageal reflux disease in Japan: analysis of claims data

Figures & data

Figure 1. Algorithm for identification of gastroesophageal reflux disease patients. The population, 1,396,262 people insured during all calendar months of 2013 and at least 1 calendar month of 2014, was analyzed. N = number of patients taking 2014 as the base year. GERD, gastroesophageal reflux disease; GU, gastric ulcer; DU, duodenal ulcer; PU, peptic ulcer (site unspecified); PPI, proton pump inhibitor; H₂RA, histamine H₂ receptor antagonist; NSAID, nonsteroidal anti-inflammatory drug; LDA, low-dose aspirin.

Figure 2. (A) Prevalence rate and (B) Incidence rate of gastroesophageal reflux disease by age and sex.

Table 1. Incidence rates of gastroesophageal reflux disease from 2009–2014.

	Year
	2009	2010	2011	2012	2013	2014
Size of population at risk	580,828	768,856	997,483	1,347,903	1,566,339	1,349,281
Number of newly-diagnosed GERD patients	3658	6003	7935	11,305	13,504	13,274
Incidence (%)	0.63%	0.78%	0.80%	0.84%	0.86%	0.98%
90% CI Upper	0.65%	0.80%	0.81%	0.85%	0.87%	1.00%
Lower	0.61%	0.76%	0.78%	0.83%	0.85%	0.97%

GERD, gastroesophageal reflux disease.

Figure 3. Medical costs per patient per month for (A) males and (B) females. PPPM, per patient per month; JPY, Japanese yen.

Figure 4. Change in medical costs per patient per month for newly-diagnosed gastroesophageal reflux disease patients. PPPM, per patient per month; JPY, Japanese yen.

Figure 5. Percentage of patients prescribed each drug class grouped by number of doctor visit months during 24 months after index month. PPI, proton pump inhibitor; H₂RA, histamine H₂ receptor antagonist; PPPM, per patient per month.

Figure 6. Newly-diagnosed gastroesophageal reflux disease patients with 19–24 doctor visit months grouped by number of proton pump inhibitor prescription months. PPI, proton pump inhibitor.